
Poolbeg Pharma starts POLB 001 trial at six NHS hospitals to block cytokine storm
A London biotech is testing an oral drug to make blood-cancer immunotherapy safer by preventing CRS in NHS patients.
By Hessa Al-Faleh·· 3 min
1 briefing · “crs”

A London biotech is testing an oral drug to make blood-cancer immunotherapy safer by preventing CRS in NHS patients.